John Bishop - Lyra Therapeutics Chief Officer
| LYRA Stock | USD 0.20 0.08 28.57% |
Executive
John Bishop is Chief Officer of Lyra Therapeutics
| Age | 62 |
| Address | 480 Arsenal Way, Watertown, MA, United States, 02472 |
| Phone | 617 393 4600 |
| Web | https://lyratherapeutics.com |
Lyra Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4229) % which means that it has lost $0.4229 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8618) %, meaning that it created substantial loss on money invested by shareholders. Lyra Therapeutics' management efficiency ratios could be used to measure how well Lyra Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 14, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.57. At present, Lyra Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 39.7 M, whereas Total Assets are forecasted to decline to about 78.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Steven CPA | NextCure | 61 | |
| Udayan MD | NextCure | N/A | |
| Colleen Sjogren | Nuvation Bio | 54 | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Kevin Shaw | NextCure | 49 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Nathan Ihle | Bolt Biotherapeutics | N/A | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Michael Alonso | Bolt Biotherapeutics | N/A | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.42 |
Lyra Therapeutics Leadership Team
Elected by the shareholders, the Lyra Therapeutics' board of directors comprises two types of representatives: Lyra Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lyra. The board's role is to monitor Lyra Therapeutics' management team and ensure that shareholders' interests are well served. Lyra Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lyra Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dr Roberts, CoFounder | ||
| Corinne Noyes, Senior Development | ||
| Donald MBA, Advisor | ||
| Gloria Cosgrove, Senior Quality | ||
| Ellen Cavaleri, Senior Communications | ||
| Richard MD, Chief Officer | ||
| Ronan JD, Chief Officer | ||
| Robert MD, Chief Advisor | ||
| John Bishop, Chief Officer | ||
| Maria Palasis, President CEO | ||
| Vineeta Belanger, Senior Affairs | ||
| Harlan MD, Executive Chairman | ||
| Robert Richard, Senior Operations | ||
| Jason Cavalier, Treasurer CFO | ||
| Ray Knox, Vice Operations |
Lyra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lyra Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (49.43) % | ||||
| Current Valuation | (3.36 M) | ||||
| Shares Outstanding | 65.46 M | ||||
| Shares Owned By Insiders | 0.65 % | ||||
| Shares Owned By Institutions | 57.98 % | ||||
| Number Of Shares Shorted | 2.04 M | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 9.53 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lyra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.023 | Quarterly Revenue Growth (0.64) | Return On Assets (0.42) | Return On Equity (1.86) |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.